This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Theradiag | |
|---|---|
| Name | Theradiag |
| Type | Public |
| Industry | Biotechnology |
| Founded | 2002 |
| Headquarters | Croissy-Beaubourg, France |
| Key people | Christophe Chammas (CEO) |
| Products | Diagnostic assays, companion diagnostics |
| Revenue | (see Financial performance) |
Theradiag is a French biotechnology company specializing in in vitro diagnostics and companion diagnostics for precision medicine, with a focus on autoimmune diseases, oncology, and infectious diseases. Founded in 2002, the company develops immunoassays and molecular tests intended to support therapeutic drug monitoring and patient stratification in clinical practice. Theradiag operates within the European healthcare and life sciences ecosystem and engages with academic centers, hospital networks, and pharmaceutical companies.
Theradiag was founded in 2002 amid growing interest in personalized medicine and pharmacogenomics, following trends exemplified by companies associated with the Human Genome Project and by diagnostic innovators in France and Europe. Early milestones included registering assays for therapeutic drug monitoring and obtaining accreditation aligned with standards set by European Medicines Agency and national agencies. The company navigated regulatory landscapes shaped by directives such as the In Vitro Diagnostic Regulation and collaborated with academic groups affiliated with institutions like Assistance Publique – Hôpitaux de Paris and university hospitals in Lyon and Paris. Over time, Theradiag expanded its product portfolio through in-house development, strategic partnerships, and participation in research consortia funded by entities such as the European Commission and regional innovation funds.
Theradiag’s operations encompass assay development, manufacturing, commercialization, and laboratory services. Product lines include enzyme-linked immunosorbent assays and automated immunoassays intended for monitoring biologic therapies used in treatment protocols influenced by guidelines from bodies such as Haute Autorité de Santé and European Crohn's and Colitis Organisation. The company supplies companion diagnostics to support immunomodulatory drugs developed by pharmaceutical firms and works with contract research organizations and hospital laboratories to implement therapeutic drug monitoring workflows. Distribution channels include medical distributors, hospital procurement managed by purchasing groups like Groupeement Hospitalier de Territoire, and direct sales to reference labs. Manufacturing and quality management draw upon standards comparable to those adopted by diagnostics manufacturers in Germany, United Kingdom, and United States markets.
Theradiag invests in R&D collaborations with academic research institutes, clinical trial networks, and biotechnology partners. Research themes align with biomarkers for autoimmune disorders, therapeutic drug monitoring for monoclonal antibodies, and assay validation in cohorts from centers such as Institut Pasteur, university hospitals affiliated with Sorbonne University, and regional clinical research centers. The company participates in translational projects that intersect with fields advanced by groups at Inserm, biotechnology clusters in Ile-de-France, and European research initiatives. R&D outputs include analytical validation studies, clinical performance evaluations, and publications co-authored with clinicians and principal investigators from tertiary care centers and specialty societies.
Theradiag targets markets in France, wider European Union, and selected international territories, leveraging partnerships with diagnostic distributors, hospital laboratories, and pharmaceutical companies seeking companion diagnostics for biologic therapeutics. Strategic alliances have been formed with contract manufacturers, clinical laboratories accredited under national schemes, and research networks spanning hospitals in regions such as Île-de-France and Auvergne-Rhône-Alpes. The company engages with pharmaceutical partners active in biologics development and with diagnostic networks that include reference laboratories associated with university hospitals and specialist societies like the European Crohn's and Colitis Organisation and national gastroenterology associations. Commercialization strategies reflect interactions with payers and health technology assessment bodies including Haute Autorité de Santé.
Theradiag’s financial profile has been influenced by product sales, service contracts with hospital laboratories, R&D grants from public and private sources, and collaborations with pharmaceutical partners. Revenue streams reflect diagnostic reagent sales, service fees for laboratory testing, and milestone payments from partnership agreements. Financial reporting cadence aligns with practices on exchanges where similar life sciences companies are listed, and capital structure has been shaped by equity financing rounds, institutional investors, and possible public market activity common to French biotech firms.
Theradiag is managed by an executive leadership team and overseen by a board of directors or supervisory board consistent with corporate governance norms in France. Senior management includes roles such as chief executive officer, chief financial officer, and heads of R&D and commercial operations, engaging with external auditors, legal advisors, and scientific advisory boards composed of clinicians and academics from university hospitals and research institutes.
Theradiag’s regulatory strategy addresses conformity with the In Vitro Diagnostic Regulation in the European Union and with national competent authorities such as agencies in France. Quality systems are implemented to meet standards comparable to ISO norms and are benchmarked against practices at diagnostics manufacturers and clinical laboratories accredited by national schemes. The company interacts with regulatory pathways relevant to companion diagnostics and engages with hospital ethics committees and clinical research oversight bodies when conducting performance studies in collaboration with university hospitals and research centers.
Category:Biotechnology companies of France Category:Medical device companies of France